The prevalence of atrial fibrillation in a geographically well‐defined population in Northern Sweden: implications for anticoagulation prophylaxis

• Published in: Journal of Internal Medicine
• Main Authors: Andersson, P., Löndahl, M., Abdon, N.‐J., Terent, A.
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2012
• Subjects: Northern Sweden
• Online Access: http://dx.doi.org/10.1111/j.1365-2796.2012.02519.x; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2796.2012.02519.x; https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2796.2012.02519.x

Abstract. Andersson P, Löndahl M, Abdon N‐J, Terent A (Hudiksvall Hospital, Hudiksvall; Lund University, Lund; and Uppsala University, Uppsala; Sweden). The prevalence of atrial fibrillation in a geographically well‐defined population in Northern Sweden: implications for anticoagulation prophylaxis. J Intern Med 2012; 272 : 170–176. Objectives. The aims of this study were to evaluate the community‐based prevalence of atrial fibrillation (AF) in a western society using a geographically well‐defined population in the northern part of Sweden as a reference and to estimate the proportion of patients eligible for oral anticoagulation (OAC) prophylactic therapy according to the stroke risk indices CHADS 2 and CHA 2 DS 2 ‐VASc. Bleeding risk was assessed using the HAS‐BLED score. Design. The study population was recruited from AURICULA, a Swedish national quality register for patients receiving anticoagulation treatment. All patients with the diagnosis AF in the catchment area are registered in AURICULA. Results. Of the 65 532 inhabitants in the catchment area, 1616 were diagnosed with AF (1200 cases were characterized as chronic AF). Thus, the overall prevalence of AF was 2.5%. The prevalence increased with age from 6.3% in patients over 55 years of age to 13.8% in those over 80 years. The prevalence was higher in men than in women in all age groups. Overall, 56.3% and 85.1% of the population were at high risk of stroke (≥2 points) according to CHADS 2 and CHA 2 DS 2 ‐VASc, respectively. In addition, 26.9% had an increased bleeding risk according to HAS‐BLED. Conclusion. Within this large Caucasian population, we identified the highest community‐based prevalence of AF to date. The prevalence was strongly associated with increasing age and male gender. Using CHA 2 DS 2 ‐VASc instead of CHADS 2 widened the indication for OAC prophylactic therapy of AF in this population.